BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29597170)

  • 1. Identification of multi-target inhibitors of leukotriene and prostaglandin E
    Gür ZT; Çalışkan B; Garscha U; Olgaç A; Schubert US; Gerstmeier J; Werz O; Banoglu E
    Eur J Med Chem; 2018 Apr; 150():876-899. PubMed ID: 29597170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP).
    Pergola C; Gerstmeier J; Mönch B; Çalışkan B; Luderer S; Weinigel C; Barz D; Maczewsky J; Pace S; Rossi A; Sautebin L; Banoglu E; Werz O
    Br J Pharmacol; 2014 Jun; 171(12):3051-64. PubMed ID: 24641614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly.
    Garscha U; Voelker S; Pace S; Gerstmeier J; Emini B; Liening S; Rossi A; Weinigel C; Rummler S; Schubert US; Scriba GK; Çelikoğlu E; Çalışkan B; Banoglu E; Sautebin L; Werz O
    Biochem Pharmacol; 2016 Nov; 119():17-26. PubMed ID: 27592027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP).
    Banoglu E; Çelikoğlu E; Völker S; Olgaç A; Gerstmeier J; Garscha U; Çalışkan B; Schubert US; Carotti A; Macchiarulo A; Werz O
    Eur J Med Chem; 2016 May; 113():1-10. PubMed ID: 26922224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7.
    Levent S; Gerstmeier J; Olgaç A; Nikels F; Garscha U; Carotti A; Macchiarulo A; Werz O; Banoglu E; Çalışkan B
    Eur J Med Chem; 2016 Oct; 122():510-519. PubMed ID: 27423639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel potent benzimidazole-based microsomal prostaglandin E
    Ergül AG; Maz TG; Kretzer C; Olğaç A; Jordan PM; Çalışkan B; Werz O; Banoglu E
    Eur J Med Chem; 2022 Mar; 231():114167. PubMed ID: 35152061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP).
    Banoglu E; Çalişkan B; Luderer S; Eren G; Özkan Y; Altenhofen W; Weinigel C; Barz D; Gerstmeier J; Pergola C; Werz O
    Bioorg Med Chem; 2012 Jun; 20(12):3728-41. PubMed ID: 22607880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibition of human 5-lipoxygenase and microsomal prostaglandin E₂ synthase-1 by the anti-carcinogenic and anti-inflammatory agent embelin.
    Schaible AM; Traber H; Temml V; Noha SM; Filosa R; Peduto A; Weinigel C; Barz D; Schuster D; Werz O
    Biochem Pharmacol; 2013 Aug; 86(4):476-86. PubMed ID: 23623753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a benzenesulfonamide-based dual inhibitor of microsomal prostaglandin E
    Cheung SY; Werner M; Esposito L; Troisi F; Cantone V; Liening S; König S; Gerstmeier J; Koeberle A; Bilancia R; Rizza R; Rossi A; Roviezzo F; Temml V; Schuster D; Stuppner H; Schubert-Zsilavecz M; Werz O; Hanke T; Pace S
    Eur J Med Chem; 2018 Aug; 156():815-830. PubMed ID: 30053720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simple heteroaryl modifications in the 4,5-diarylisoxazol-3-carboxylic acid scaffold favorably modulates the activity as dual mPGES-1/5-LO inhibitors with in vivo efficacy.
    Gürses T; Olğaç A; Garscha U; Gür Maz T; Bal NB; Uludağ O; Çalışkan B; Schubert US; Werz O; Banoglu E
    Bioorg Chem; 2021 Jul; 112():104861. PubMed ID: 33826984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 1,3,4-oxadiazole derivatives as highly potent microsomal prostaglandin E
    Gür Maz T; Dahlke P; Gizem Ergül A; Olğaç A; Jordan PM; Çalışkan B; Werz O; Banoglu E
    Bioorg Chem; 2024 Jun; 147():107383. PubMed ID: 38653151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel leukotriene biosynthesis inhibitors (2012-2016) as anti-inflammatory agents.
    Werz O; Gerstmeier J; Garscha U
    Expert Opin Ther Pat; 2017 May; 27(5):607-620. PubMed ID: 28005436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.
    Gür ZT; Çalışkan B; Banoglu E
    Eur J Med Chem; 2018 Jun; 153():34-48. PubMed ID: 28784429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 5-lipoxygenase inhibitor RF-22c potently suppresses leukotriene biosynthesis in cellulo and blocks bronchoconstriction and inflammation in vivo.
    Schaible AM; Filosa R; Krauth V; Temml V; Pace S; Garscha U; Liening S; Weinigel C; Rummler S; Schieferdecker S; Nett M; Peduto A; Collarile S; Scuotto M; Roviezzo F; Spaziano G; de Rosa M; Stuppner H; Schuster D; D'Agostino B; Werz O
    Biochem Pharmacol; 2016 Jul; 112():60-71. PubMed ID: 27157409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ginkgolic Acid is a Multi-Target Inhibitor of Key Enzymes in Pro-Inflammatory Lipid Mediator Biosynthesis.
    Gerstmeier J; Seegers J; Witt F; Waltenberger B; Temml V; Rollinger JM; Stuppner H; Koeberle A; Schuster D; Werz O
    Front Pharmacol; 2019; 10():797. PubMed ID: 31379572
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel benzoxanthene lignans that favorably modulate lipid mediator biosynthesis: A promising pharmacological strategy for anti-inflammatory therapy.
    Gerstmeier J; Kretzer C; Di Micco S; Miek L; Butschek H; Cantone V; Bilancia R; Rizza R; Troisi F; Cardullo N; Tringali C; Ialenti A; Rossi A; Bifulco G; Werz O; Pace S
    Biochem Pharmacol; 2019 Jul; 165():263-274. PubMed ID: 30836057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encapsulation of the dual FLAP/mPEGS-1 inhibitor BRP-187 into acetalated dextran and PLGA nanoparticles improves its cellular bioactivity.
    Shkodra-Pula B; Kretzer C; Jordan PM; Klemm P; Koeberle A; Pretzel D; Banoglu E; Lorkowski S; Wallert M; Höppener S; Stumpf S; Vollrath A; Schubert S; Werz O; Schubert US
    J Nanobiotechnology; 2020 May; 18(1):73. PubMed ID: 32408877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand-based Modeling for the Prediction of Pharmacophore Features for Multi-targeted Inhibition of the Arachidonic Acid Cascade.
    Saroj Devi N; Shanmugam R; Ghorai J; Ramanan M; Anbarasan P; Doble M
    Mol Inform; 2018 Mar; 37(3):. PubMed ID: 28991413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological cross-reactivity between 5-lipoxygenase-activating protein, 5-lipoxygenase, and leukotriene C4 synthase.
    Gupta N; Nicholson DW; Ford-Hutchinson AW
    Can J Physiol Pharmacol; 1997; 75(10-11):1212-9. PubMed ID: 9431445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethoxy acetalated dextran-based nanocarriers accomplish efficient inhibition of leukotriene formation by a novel FLAP antagonist in human leukocytes and blood.
    Kretzer C; Shkodra B; Klemm P; Jordan PM; Schröder D; Cinar G; Vollrath A; Schubert S; Nischang I; Hoeppener S; Stumpf S; Banoglu E; Gladigau F; Bilancia R; Rossi A; Eggeling C; Neugebauer U; Schubert US; Werz O
    Cell Mol Life Sci; 2021 Dec; 79(1):40. PubMed ID: 34971430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.